1. Intensive therapy with gastropodan hemocyanins increases their antitumor properties in murine model of colon carcinoma.
- Author
-
Stoyanova E, Mihaylova N, Manoylov I, Bradyanova S, Raynova Y, Idakieva K, and Tchorbanov A
- Subjects
- Animals, Antineoplastic Agents pharmacology, Cell Line, Tumor, Colonic Neoplasms blood, Colonic Neoplasms immunology, Colonic Neoplasms pathology, Cytokines blood, Disease Models, Animal, Female, Hemocyanins pharmacology, Immunoglobulin G blood, Immunotherapy, Mice, Inbred BALB C, Plasma Cells, Antineoplastic Agents therapeutic use, Colonic Neoplasms drug therapy, Hemocyanins therapeutic use, Snails chemistry
- Abstract
Various natural compounds have been tested as anticancer therapeutics in clinical trials. Most promising direction for antitumor therapy is the use of substances which enhance the immune system response stimulating tumor-specific lymphocytes. Hemocyanins are large extracellular oxygen transport glycoproteins isolated from different arthropod and mollusk species which exhibit strong anticancer properties. Immunized in mammals they trigger Th1 immune response that promotes unspecific stimulation and adjuvant activity in experimental therapeutic vaccines for cancer and antibody development. In the present study we used two hemocyanins - one isolated from marine snail Rapana thomasiana (RtH) and another one, from the terrestrial snail Helix pomatia (HpH) which have been investigated by using different administration schedules (intensive and mild) in murine model of colon carcinoma. The treatment with RtH and HpH generated high levels of antitumor IgG antibodies, antibody-producing plasma cells and tumor-specific CTLs, stimulated secretion of proinflammatory cytokines, suppressed the manifestation of carcinoma symptoms as tumor growth and size, and prolonged the life span of treated mice. Our results showed a significant anti-cancer effect of RtH and HpH hemocyanins on a murine model of colon carcinoma with promising potential for immunotherapy in various schemes of administration based on cross-reactive tumor-associated epitopes., Competing Interests: Declaration of Competing Interes None of the authors has any potential conflict of interest related to this manuscript., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF